Edge Therapeutics (EDGE) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Edge Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results
March 8, 2016 7:00 AM ESTBERKELEY HEIGHTS, N.J., March 08, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management of acute, life threatening conditions, today announced financial results and corporate highlights for the fourth quarter and full-year ended December 31, 2015.
2015 was a transformative year for Edge, said Brian A. Leuthner, Edges President and Chief Executive Officer. We completed our Phase 1/2 NEWTON study with our lead program EG-1962, which met all primary and secondary endpoints and showed favorable outcome data. In addition, we raised net proceeds... More
